ALK and non-small cell lung carcinoma: In non-squamous NSCLC patients, we found higher rates of targetable mutations in EGFR, ALK, and ROS1 (19%, 10%, 4%) than that expected in a typical NSCLC age-unrestricted UK population [2,3].